Sustained API pricing pressure
API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
medium · management_commentary
Aurobindo Pharma Limited — Q1 FY26
Aurobindo Pharma reported a steady Q1 FY26 with consolidated revenue of INR 7,878 crore (+4% YoY) and EBITDA of INR 1,603 crore (+12% YoY), despite a significant reduction in ge...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
FTC approval delay for Lannett acquisition
The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.
medium · analyst_questionGeneric Revlimid revenue tailwind fading
Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.
high · management_commentaryU.S. tariff and domestic manufacturing push uncertainty
Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.
medium · analyst_question